Eosinophilia-myalgia syndrome: Patient status 2-4 years after onset

Journal of Rheumatology

Volumn 23, Issue SUPPL. 46, 1996, Pages 19-25

  Pincus, Theodore ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

eosinophilia myalgia syndrome; longterm course; outcomes

Indexed keywords

ACETYLSALICYLIC ACID; ALPRAZOLAM; AMITRIPTYLINE; AZATHIOPRINE; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOBENZAPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYPROHEPTADINE; DANTROLENE; DEXTROPROPOXYPHENE; DIPHENHYDRAMINE; FLUOXETINE; FUROSEMIDE; HYDROXYCHLOROQUINE; HYDROXYZINE; IBUPROFEN; METHOTREXATE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PENICILLAMINE; PYRIDOXINE; QUININE; RANITIDINE; THYROXINE; TRIAZOLAM; TRYPTOPHAN; UNINDEXED DRUG;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; EOSINOPHILIA MYALGIA SYNDROME; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SELF REPORT; TREATMENT OUTCOME; ARTICLE; LONGITUDINAL STUDY; PATHOPHYSIOLOGY; PATIENT; PHYSICIAN; QUESTIONNAIRE; REGISTER;

EOSINOPHILIA-MYALGIA SYNDROME; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; PATIENTS; PHYSICIANS; QUESTIONNAIRES; REGISTRIES; TREATMENT OUTCOME;

EID: 0029805718     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (38)

1. Centers for Disease Control: Update: Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan - United States, as of January 9, 1990 (from MMWR Morb Mortal Wkly Rep 1990;39:14-5). JAMA 1990;263:633.
2. Centers for Disease Control: Update: Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan - United States, as of January 9, 1990 (from MMWR Morb Mortal Wkly Rep 1990;39:14-5). JAMA 1990;263:633.
3. Clauw DJ, Nashel DJ, Umhau A, Katz P: Tryptophan-associated eosinophilic connective-tissue disease: A new clinical entity? JAMA 1990;263:1502-6.
4. Freundlich B, Werth VP, Rook AH, et al: L-Tryptophan ingestion associated with eosinophilic fasciitis but not progressive systemic sclerosis. Ann Intern Med 1990;112:758-62.
5. Culpepper RC, Williams RG, Mease PJ, Koepsell TD, Kobayashi JM: Natural history of the eosinophilia-myalgia syndrome. Ann Intern Med 1991;115:437-42.
6. Kaufman LD, Gruber BL, Gregersen PK: Clinical follow-up and immunogenetic studies of 32 patients with eosinophilia-myalgia syndrome. Lancet 1991;337:1071-4.
7. Philen RM, Eidson M, Kilbourne EM, Sewell CM, Voorhees R, New Mexico Eosinophilia-Myalgia Syndrome Study Group: Eosinophilia-myalgia syndrome: A clinical case series of 21 patients. Arch Intern Med 1991;151:533-7.
8. Silver RM: Unraveling the eosinophilia-myalgia syndrome (editorial). Arch Dermatol 1991;121:1214-6.
9. Thacker H: Eosinophilia-myalgia syndrome: The Cleveland Clinic experience. Cleve Clin J Med 1991;58:400-8.
10. Varga J, Griffin R, Newman JH, Jimenez SA: Eosinophilic fasciitis is clinically distinguishable from the eosinophilia-myalgia syndrome and is not associated wich L-tryptophan use. J Rheumatol 1991;18:259-63.
11. Kilbourne EM: Eosinophilia-myalgia syndrome: Coming to grips with a new illness. Epidemiol Rev 1992;14:16-36.
12. Duffy J: The lessons of eosinophilia-myalgia syndrome. Hosp Pract 1992;65-90.
13. Sack KE, Criswell LA: Eosinophilia-myalgia syndrome: The aftermath. South Med J 1992;85:878-82.
14. Kaufman LD: Chronicity of the eosinophilia-myalgia syndrome. Arthritis Rheum 1994;37:84-7.
15. Kaufman LD: The evolving spectrum of the eosinophilia-myalgia syndrome. Rheum Dis Clin North Am 1994;20:973-94.
16. Hertzman PA, Clauw DJ, Kaufman LD, et al: The eosinophilia-myalgia syndrome: Status of 205 patients and results of treatment 2 years after onset. Ann Intern Med 1995;122:851-5.
17. Pincus T, Marcum SB, Callahan LF, et al: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: I. Nonsteroidal anti-inflammatory drugs. J Rheumatol 1992;19:1874-84.
18. Pincus T, Brooks RH, Callahan LF: Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Ann Intern Med 1994;120:26-34.
19. Pincus T, Callahan LF: Eosinophilia-myalgia syndrome: Initial results of a survey concerning experience of rheumatologists (abstr). Arthritis Rheum 1991;(suppl)36:S144.
20. Pincus T, Oeser AM: Eosinophilia-myalgia syndrome: Self-report of status of 344 patients 4 years after disease onset (abstr). Arthritis Rheum 1994;(suppl)37:R25.
21. Centers for Disease Control: Update: Eosinophilia-myalgia syndrome associated with ingestion of L-tryptophan - United States, through August 24, 1990. MMWR Morb Mortal Wkly Rep 1990;39:587-9.
22. Pincus T, Summey JA, Soraci SA Jr, Wallston KA, Hummon NP: Assessment of patient satisfaction in activities of daily living using a modified Stanford health assessment questionnaire. Arthritis Rheum 1983;26:1346-53.
23. Pincus T, Callahan LF, Brooks RH, Fuchs HA, Olsen NJ, Kaye JJ: Self-report questionnaire scores in rheumatoid arthritis compared with traditional physical, radiographic, and laboratory measures. Ann Intern Med 1989;110:259-66.
24. Wolfe F, Pincus T: Standard self-report questionnaires in routine clinical and research practice - an opportunity for patients and rheumatologists. J Rheumatol 1991;18:643-6.
25. Callahan LF, Brooks RH, Summey JA. Pincus T: Quantitative pain assessment for routine care of rheumatoid arthritis patients, using a pain scale based on activities of daily living and a visual analog pain scale. Arthritis Rheum 1987;30:630-6.
26. Nicassio PM, Wallston KA, Callahan LF, Herbert M, Pincus T: The measurement of helplessness in rheumatoid arthritis. The development of the Arthritis Helplessness Index. J Rheumatol 1985;12:462-7.
27. Callahan LF, Brooks RH, Pincus T: Further analysis of learned helplessness in rheumatoid arthritis using a "Rheumatology Attitudes Index". J Rheumatol 1988;15:418-26.
28. DeVellis RF, Callahan LF: A brief measure of helplessness in rheumatic disease: The helplessness subscale of the Rheumatology Attitudes Index. J Rheumatol 1993;20:866-9.
29. Krupp LB, Masur DM, Kaufman LD: Neurocognitive dysfunction in the eosinophiha-myalgia syndrome. Neurology 1993;43:931-6.
30. Gaudino EA, Masur DM, Kaufman LD, Sliwinski M, Krupp LB: Depression and neuropsychological performance in the eosinophilia myalgia syndrome: A comprehensive analysis of cognitive function in a chronic illness. Neuropsychiatry, Neuropsychology, and Behavioral Neurology 1995;8:118-26.
31. Hertzman PA, Kaufman LD, Love LA, et al: The eosinophilia-myalgia syndrome - Guidelines for patient care. J Rheumatol 1995;22:161-3.
32. Eidson M, Philen RM, Sewell CM, Voorhees R, Kilbourne EM: L-tryptophan and eosinophilia-myalgia syndrome in New Mexico. Lancet 1990;335:645-8.
33. Swygert LA, Maes EF, Sewell LE, Miller L, Falk H, Kilbourne EM: Eosinophilia-myalgia syndrome: Results of national surveillance. JAMA 1990;264:1698-703.
34. Hedberg K, Urbach D, Slutsker L, Matson P, Fleming D: Eosinophilia-myalgia syndrome: Natural history in a population based cohort. Arch Intern Med 1992;152:1889-92.
35. Horwitz RI, Daniels SR: Bias or biology: Evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome. J Rheumatol 1996;(suppl 46)23:60-72.
36. Shapiro S: Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome. A critique. J Rheumatol 1996;(suppl 46)23:44-59.
37. Spitzer WO, Haggerty JL, Berkson L, et al: Analysis of Centers for Disease Control and Prevention criteria for the eosinophilia-myalgia syndrome in a geographically defined population. J Rheumatol 1996;(suppl 46)23:73-80.
38. Clauw DJ: Animal models of the eosinophilia-myalgia syndrome. J Rheumatol 1996;(suppl 46)23:93-8.